Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.

Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.

View in: PubMed

subject areas

Adult
Adult
Antibodies, Antiphospholipid
Antibodies, Antiphospholipid
Anticoagulants
Anticoagulants
Antigens, CD
Antigens, CD
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents, Non-Steroidal
Antiphospholipid Syndrome
Antiphospholipid Syndrome
Aspirin
Aspirin
Biomarkers
Biomarkers
Endoglin
Endoglin
Female
Female
Fetal Growth Retardation
Fetal Growth Retardation
Gestational Age
Gestational Age
Heparin
Heparin
Humans
Humans
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Placenta Growth Factor
Placenta Growth Factor
Predictive Value of Tests
Predictive Value of Tests
Pre-Eclampsia
Pre-Eclampsia
Pregnancy
Pregnancy
Pregnancy Outcome
Pregnancy Outcome
Pregnancy Proteins
Pregnancy Proteins
Pregnancy Trimester, First
Pregnancy Trimester, First
Pregnancy Trimester, Second
Pregnancy Trimester, Second
Pregnancy, High-Risk
Pregnancy, High-Risk
Prospective Studies
Prospective Studies
Receptors, Cell Surface
Receptors, Cell Surface
Severity of Illness Index
Severity of Illness Index
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-1
Young Adult
Young Adult

authors with profiles

Joan Merrill